Abstract:Microsporidia are fungi obligate intracellular pathogens, which infect most animals and cause microsporidiosis. Despite the serious threat that microsporidia pose to humans and agricultural animals, few drugs are available for the treatment and control of microsporidia. To identify novel inhibitors, we took advantage of the model organism Caenorhabditis elegans infected with its natural microsporidian Nematocida parisii. We used this system to screen the Pandemic Response Box, a collection of 400 diverse compounds with known antimicrobial activity. After testing these compounds in a 96-well format at high (100 mu M) and low (40 mu M) concentrations, we identified four inhibitors that restored the ability of C. elegans to produce progeny in the presence of N. parisii. All four compounds reduced the pathogen load of both N. parisii and Pancytospora epiphaga, a C. elegans-infecting microsporidia related to human-infecting species. One of these compounds, a known inhibitor of a viral protease, MMV1006203, inhibited invasion and prevented the firing of spores. A bis-indole derivative, MMV1593539, decreased spore viability. An albendazole analog, MMV1782387, inhibited proliferation of N. parisii. We tested albendazole as well as 5 other analogs and observed that MMV1782387 was amongst the strongest inhibitors of N. parisii and displayed the least host toxicity. Our study further demonstrates the effectiveness of the C. elegans-N. parisii system for discovering microsporidia inhibitors and the compounds we identified provide potential scaffolds for anti-microsporidia drug development. Microsporidia are a large group of parasites which infect both humans and agriculturally important animals such as honey bees and shrimp. These parasites pose a threat to health and food security and there are few therapeutic options available to treat them. To identify compounds that could inhibit microsporidia, we took advantage of the roundworm model organism Caenorhabditis elegans, and the microsporidia Nematocida parisii which naturally infects this worm. We then used this system to screen the Pandemic Response Box, which is a collection of compounds with activity towards pathogens. We identified four compounds which could inhibit microsporidia, and found that these compounds worked by either inactivating microsporidia spores, preventing microsporidia germination, or hindering the growth of the parasite. Together this work provides compounds that could be used to study microsporidia infection and that could be a starting point for the development of drugs against these parasites.

Novel Compound MMV1804559 from the Global Health Priority Box Exhibits In Vitro and In Vivo Activity against Madurella mycetomatis

Three Small Molecule Entities (MPK18, MPK334 and YAK308) with Activity against Haemonchus contortus In Vitro

Screening of the Open Source Malaria Box Reveals an Early Lead Compound for the Treatment of Alveolar Echinococcosis

Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella

Screening of the Pandemic Response Box Identifies Anti-Microsporidia Compounds

In Vitro Screening of the Open-Source Medicines for Malaria Venture Malaria and Pathogen Boxes To Discover Novel Compounds with Activity against Balamuthia mandrillaris

Protoplast-mediated transformation of Madurella mycetomatis using hygromycin resistance as a selection marker

In vitro susceptibility testing for black grain eumycetoma causative agents

Functional Phenotyping of MMV Pandemic Response Box Identifies Stage-specific inhibitors Against Blood stage Plasmodium

Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box

Identification and preclinical evaluation of MMV676558 as a promising therapeutic candidate against Clostridioides difficile

Heterocycle-Substituted Α-Methylene-γ-butyrolactones Derivatives Synthesis, Antifungal Activity, and 3D-QSAR.

New possibilities for chromoblastomycosis and phaeohyphomycosis treatment: identification of two compounds from the MMV Pathogen Box® that present synergism with itraconazole

On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity

A Screening of the MMV Pandemic Response Box Reveals Epetraborole as A New Potent Inhibitor against Mycobacterium abscessus

Global Health Priority Box: Discovering Flucofuron as a Promising Antikinetoplastid Compound

Synthesis, Bioactivity and Preliminary Mechanism of Action of Novel Trifluoromethyl Pyrimidine Derivatives

Design, Synthesis, and Antifungal Evaluation of Novel Pyrazole-5-sulfonamide Derivatives for Plant Protection

Preliminary Structure–Activity Relationship Study of the MMV Pathogen Box Compound MMV675968 (2,4-Diaminoquinazoline) Unveils Novel Inhibitors of Trypanosoma brucei brucei

Broad-Spectrum Inhibitors for Conserved Unique Phosphoethanolamine Methyltransferases in Parasitic Nematodes Possess Anthelmintic Efficacy

Comparative Structure Activity and Target Exploration of 1,2-Diphenylethynes in Haemonchus Contortus and Caenorhabditis Elegans